» Articles » PMID: 38693106

New Perspective on Sustained Antidepressant Effect: Focus on Neurexins Regulating Synaptic Plasticity

Overview
Date 2024 May 1
PMID 38693106
Authors
Affiliations
Soon will be listed here.
Abstract

Depression is highly prevalent globally, however, currently available medications face challenges such as low response rates and short duration of efficacy. Additionally, depression mostly accompany other psychiatric disorders, further progressing to major depressive disorder without long-term effective management. Thus, sustained antidepressant strategies are urgently needed. Recently, ketamine and psilocybin gained attention as potential sustained antidepressants. Review of recent studies highlights that synaptic plasticity changes as key events of downstream long-lasting changes in sustained antidepressant effect. This underscores the significance of synaptic plasticity in sustained antidepressant effect. Moreover, neurexins, key molecules involved in the regulation of synaptic plasticity, act as critical links between synaptic plasticity and sustained antidepressant effects, involving mechanisms including protein level, selective splicing, epigenetics, astrocytes, positional redistribution and protein structure. Based on the regulation of synaptic plasticity by neurexins, several drugs with potential for sustained antidepressant effect are also discussed. Focusing on neurexins in regulating synaptic plasticity promises much for further understanding underlying mechanisms of sustained antidepressant and the next step in new drug development. This research represents a highly promising future research direction.

Citing Articles

Single prolonged stress induces behavior and transcriptomic changes in the medial prefrontal cortex to increase susceptibility to anxiety-like behavior in rats.

Iqbal J, Huang G, Shen D, Xue Y, Yang M, Jia X Front Psychiatry. 2024; 15:1472194.

PMID: 39628496 PMC: 11611810. DOI: 10.3389/fpsyt.2024.1472194.

References
1.
Cunningham N . Hallucinogenic plants of abuse. Emerg Med Australas. 2008; 20(2):167-74. DOI: 10.1111/j.1742-6723.2008.01070.x. View

2.
Qu Y, Shan J, Wang S, Chang L, Pu Y, Wang X . Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling. Eur Arch Psychiatry Clin Neurosci. 2020; 271(3):439-446. DOI: 10.1007/s00406-020-01208-w. View

3.
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R . Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023; 330(9):843-853. PMC: 10472268. DOI: 10.1001/jama.2023.14530. View

4.
Wang X, Rammes G, Kraev I, Wolf M, Liebl C, Scharf S . Forebrain CRF₁ modulates early-life stress-programmed cognitive deficits. J Neurosci. 2011; 31(38):13625-34. PMC: 3380621. DOI: 10.1523/JNEUROSCI.2259-11.2011. View

5.
Hart M, Hobert O . Neurexin controls plasticity of a mature, sexually dimorphic neuron. Nature. 2018; 553(7687):165-170. PMC: 5968453. DOI: 10.1038/nature25192. View